novo nordisk glp-1 drug Details of failed studies cast pall on Nordisk's as Alzheimer's treatment Novo Nordisk promotes new GLP-1
Description
Separately, the stimulant lisdexamfetamine (Vyvanse) is FDA-approved for binge-eating disorder, which sometimes overlaps with ADHD
We continue to stay up to speed on the newest research and advances in the field to guarantee that our patients receive the best possible care
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News
GLP-1 receptor agonists offer a wide range of clinically supported benefits for individuals aiming to lose weight and improve their metabolic health
Retrieved March 10, 2026, from 15 Pennsylvania Department of Human Services
Process of studies selection
